HER3-DXd
Lung Cancer
Treatment patterns and adverse event-related hospitalization among patients with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer after treatment with EGFR tyrosine kinase inhibitor and platinum-based chemotherapy regimens
Marrett E, Kwong JW, Xie J, et al.
Drugs Real World Outcomes. 2023;10(4):531-544.
Edoxaban
Cardiovascular - AF
Prescription of DOACs in patients with atrial fibrillation at different stages of renal insufficiency
Hahn K, Lamparter M.
Adv Ther. 2023;40(10):4264-4281.
Edoxaban
Cardiovascular - AF
Cardiovascular - VTE
Edoxaban use in the context of dental procedures: Analysis from the EMIT-AF/VTE database
Chen C, Saxena M, von Heymann C, et al.
BDJ Open. 2023;9(1):38.
Valemetostat
Hematology
Safety, tolerability, and pharmacokinetics of valemetostat tablets and the effect of food on valemetostat pharmacokinetics in healthy subjects: Two phase 1 studies
Tachibana M, Matsuki S, Toyama K, et al.
Clin Pharmacol Drug Dev. 2024;13(1):77-86.
Edoxaban
Cardiovascular - AF
Comprehension of nonvalvular atrial fibrillation and anticoagulant adherence in elderly patients in a subcohort study of the All Nippon Atrial fibrillation in the Elderly registry
Akao M, Yamashita T, Atarashi H, et al.
Am J Cardiol. 2023;204:P159-167.
T-DXd
Other/Multi
Transition of average drug-to-antibody ratio of trastuzumab deruxtecan in systemic circulation in monkeys using a hybrid affinity capture liquid chromatography-tandem mass spectrometry
Habara H, Okamoto H, Nagai Y, et al.
Biopharm Drug Dispos. 2023;44(5):380-384.
Dato-DXd
Breast Cancer
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer
Dent RA, Cescon DW, Bachelot T, et al.
Future Oncol. 2023;19(35):2349-2359.
T-DXd
Gastric Cancer
Use of real-world evidence in a virtual bridging analysis for a human epidermal growth factor receptor 2-targeted antibody-drug conjugate in gastric cancer
Lu Z, Wada R, Salas M, et al.
J Clin Pharmacol. 2023;63(11):1244-1255.
T-DXd
Breast Cancer
Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland
Paulissen JHJ, Seddik AH, Dunton KJ, et al.
Eur J Health Econ. 2024;25(4):689-699.
Edoxaban
Cardiovascular - AF
Relationship between direct oral anticoagulant doses and clinical outcomes in elderly patients with non-valvular atrial fibrillation — ANAFIE Registry sub-analysis
Akao M, Inoue H, Yamashita T, et al.
Circ J. 2023;87(12):1765-1774.
